You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
TOPIC #366- PHASE II SBIR CONTRACT- CLONOGENIC HIGH- THROUGHPUT ASSAY FOR SCREENING RADIATION MODULATION
SBC: SUVICA INC Topic: NCIClonogenic assays measure the ability of single cells to proliferate and form a colonyThis process approximates closely the regrowth and recurrence of tumors after treatment with radiation or chemotherapyproviding an assay to screen for drugs that block this processYetclonogenic assays are labor intensive and too cumbersome for high throughout screeningHTSof compound librariesHere we propose to de ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
TOPIC 389- INTELLIGENT SOFTWARE FOR RADIATION THERAPY PLANNING
SBC: RADIASOFT LLC Topic: NCIBesides surgeryradiotherapy is the most effective treatment modality for localized prostate cancerThe success of radiotherapy stems from the exploit of a therapeutic window in tumor response and normal tissue tolerance which maximizes the chance of sterilizing the tumor while sparing the surrounding normal tissue from severe damageThis requires an accurate and individualized radiation dose distrib ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
A multivalent, easy-to-use product to mitigate and treat radiation exposure
SBC: FIBROPLATE INC Topic: NIAIDABSTRACTThe threat of radiological and nuclear accidents or attacks demands for effective radiation medical countermeasuresMCMable to mitigate and treat the effects of exposure to ionizing radiationsHematopoietic acute radiation syndromeHRASand cutaneous radiation syndromeCRSpose severelife threatening risks to exposed individualsCurrently no effective radio mitigatorto be administered after radia ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Developing a Small Peptide to Control Autoimmune Inflammation In Type 1 Diabetes
SBC: Op-T-Mune, Inc Topic: NIAIDType 1 Diabetes (T1D) affects an ever growing population. While this disease typically has been associated with juveniles, the disease in adult populations is rapidly increasing. The defining clinical component is insulin loss, which occurs because of sustained inflammation in the islets. At present there is no means to prevent or reverse insulin loss. A major inflammatory pathway in T1D that cont ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Personal Mercury Monitor for Exposure Measurements
SBC: LUDLUM MEASUREMENTS INC Topic: 113Personal Mercury Monitor for Exposure Measurements Project Summary/AbstractWorkers in the oil and natural gas industry are vulnerable to exposure to toxic mercury (Hg) vapor as a result of routine inspection and maintenance of equipment such as compressors and other process equipment that concentrate species of low volatility over time. Exposure of workers to elemental mercury vapor is of concern ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Bioinformatic Tools for Interpretation of Glycan Array Data
SBC: Z BIOTECH, LLC Topic: 400Project SummaryAbstract There is an urgent need of bioinformatic tools for mining glycan array data in order to accurately and statistically study the interactions between cell surface glycans and glycan binding proteinsWe propose here to develop a software and hardware integrated system for the interpretation of glycan array dataThe problem with existing glycan array data mining tools is that the ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Point-of-Care Prognostic Tool for Sepsis
SBC: MBIO DIAGNOSTICS INC Topic: 300Sepsis is a devastating cause of morbidity and mortality in intensive care units (ICUs), with estimates of U.S. incidence ranging from 894,000 to 3.1 million cases annually. The heterogeneity of clinical presentation (etiology, patient history, severity, etc.) creates a major challenge for patient management and has significantly complicated development of new therapies, almost all of which have f ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Organic photoredox catalysts as sustainable and cost-effective replacement for precious metal complexes in light-driven drug synthesis
SBC: NEW IRIDIUM, INC Topic: 300PROJECT SUMMARYLight driven chemistryor photoredox catalysishas made significant advances in the last decade for practical organic or drug synthesisFor examplelight induced reactions have enabled generation of radical intermediate Rfor direct functionalization of biologically relevant heterocycles and cross coupling reactions for important covalent bond formationsThereforephotoredox catalysis offe ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Noninvasive Functional Cortical Mapping with Innovative tEEG
SBC: CREMEDICAL CORP Topic: 106PROJECT SUMMARY Resective neurosurgery is essential for treating a range of neurologic conditions such as epilepsy and brain tumorsFor some patientswhose lesion is close to cortical language areaspostoperative expressive or receptive language deficit is a major and feared postoperative complicationMuch effort is devoted to identifying the cortical language regionsand relating such localization to ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Immunoassay for early diagnosis of mucormycosis
SBC: DXDISCOVERY INC Topic: NIAIDMucormycosis is one of the deadliest of the invasive fungal infections. Mucormycosis occurs most often in patients with hematological malignancies undergoing chemotherapy, patients who have received hematopoietic stem cell transplants or patients with diabetes mellitus. Improved diagnosis is the most frequently noted unmet need for management of the mucormycosis patient. Delays in treatment increa ...
SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health